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atients have gained 
unprecedented levels of 
control over their medical care, 
including prospective control over 
what treatments they will receive if 
they lose the ability to make decisions. 
The landmark Cruzan and Quinlan 
cases helped to secure patients’ right 
to prospectively refuse life-sustaining 
treatments [1,2], while the Patient Self-
Determination Act of 1990 mandated 
that patients be informed of the 
option to document their treatment 
preferences in an advance directive [3]. 
Despite these efforts, many 
individuals fail to complete an advance 
directive and seldom discuss their 
medical treatment preferences, often 
leaving clinicians with little indication 
for how they want to be treated [4–7]. 
Several groups have attempted to 
increase the number of people who 
complete an advance directive, and 
several approaches offer promise in 
this regard [8]. Yet, no method, no 
matter how exhaustive, will result in 
all individuals completing an advance 
directive, and no advance directive, 
no matter how detailed, will provide 
clear instructions for all clinical 
scenarios. For the foreseeable future, 
then, clinicians will continue to face 
the dilemma of how to treat some 
incapacitated patients in the absence 
of clear evidence regarding their 
treatment wishes.
Most states in the US direct clinicians 
to turn to surrogate decision makers, 
identiﬁ  ed through standardized 
relationship hierarchies, to make 
treatment decisions for incapacitated 
patients who did not designate a 
surrogate while capacitated. Surrogates, 
whether designated by the patient or 
the state’s standardized hierarchy, 
are instructed to make the treatment 
decision the patient would have made 
if capacitated. Under this “substituted 
judgment” standard, a surrogate asked 
to decide whether to initiate dialysis 
for a comatose patient, for example, 
should try to determine what decision 
the patient would have made in the 
circumstances.
The medical profession’s reliance on 
surrogates to make treatment decisions 
for incapacitated patients gains 
support from the fact that the relevant 
considerations for choosing a substitute 
decision maker all seem to point to the 
family and loved ones. Allowing the 
patient’s family and loved ones to make 
treatment decisions seems to respect 
their status as vital individuals in the 
patient’s life [9–11] and may provide 
comfort at a difﬁ  cult time. Reliance on 
those who know the patient best also 
seems to promote patient autonomy 
by maximizing the chances that the 
incapacitated patient’s preferences 
will guide what treatments they 
receive. Finally, current practice seems 
consistent with patients’ preferences 
for how treatment decisions should be 
made [12–14]. To test whether, in fact, 
these considerations all support the 
same approach, we assessed whether a 
population-based decision aid might 
predict patients’ treatment preferences 
more accurately than surrogates. 
Identifying a Potential Alternative 
to Surrogates
Recent data suggest that basing 
treatment decisions on how individuals 
similar to the patient want to be treated 
might predict patients’ treatment 
preferences more accurately than 
patients’ surrogates [15–17]. To pursue 
this possibility, we asked whether 
a population-based method that 
predicts which treatment patients want 
based on the treatment preferences 
of individuals similar to the patient 
might make more accurate predictions 
than patient designated and next of 
kin surrogates. We call this method 
a “population-based treatment 
indicator.” 
Imagine that a 70-year-old Native 
American male with a PhD and 
severe Alzheimer disease develops 
pneumonia. To decide whether to 
administer antibiotics, clinicians ﬁ  rst 
look to any evidence of the patient’s 
treatment preferences. When the 
patient’s treatment preferences are 
unknown, current practice is to ask 
the patient’s designated or next of kin 
surrogate to predict, based on their 
knowledge of the patient, whether he 
would want antibiotics. The population-
based treatment indicator, in 
contrast, predicts whether the patient 
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would want antibiotics based on the 
preferences of individuals similar to the 
patient in similar circumstances. 
Implementation of this approach 
would involve the clinician entering the 
incapacitated patient’s circumstances—
pneumonia and severe Alzheimer 
disease—and his characteristics—older, 
well educated, Native American, 
male—into a computer. The treatment 
indicator’s database analyzes the 
treatment preferences of similar 
individuals and estimates the likelihood 
that the patient would want antibiotics 
to treat his pneumonia. Physicians could 
then use this information to help them 
make a treatment decision. A ﬁ  nding 
that 90% of highly educated Native 
American men over the age of 50 do 
not want to receive antibiotics to treat 
pneumonia in the setting of advanced 
Alzheimer disease would provide strong 
evidence that this patient would not 
want antibiotics in his circumstances. 
This approach will require data 
on which characteristics inﬂ  uence 
individuals’ medical treatment 
preferences. Does gender predict 
whether individuals want to receive 
antibiotics in the setting of severe 
Alzheimer disease? Does religion? 
Ancestry? Whether one was born before 
or after the Cruzan and Quinlan cases? 
Characteristics associated with different 
treatment preferences, along with their 
probabilities, would be entered into 
the database of the population-based 
treatment indicator. As more data are 
collected, additional associations would 
be entered, thus allowing the indicator 
to cover more circumstances, and make 
more accurate treatment predictions. 
The population-based treatment 
indicator does not assume that all 
individuals of a given gender, race, 
or religion have the same medical 
treatment preferences. Rather, the 
indicator simply incorporates all and 
only those factors which the data show 
are associated with particular medical 
treatment preferences, along with the 
strength of these associations. The 
members of any given group, no matter 
how narrowly deﬁ  ned, will invariably 
have different treatment preferences in 
some cases. For this reason, physicians 
sometimes will make mistakes when 
relying on a population-based 
treatment indicator to predict the 
treatment preferences of incapacitated 
patients. Recognizing the inevitability 
of mistakes, the present analysis asks 
whether a population-based treatment 
indicator predicts patients’ treatment 
preferences more accurately than 
surrogates. This assessment involves 
three steps: 1) estimate the predictive 
accuracy of surrogates; 2) deﬁ  ne 
a preliminary population-based 
treatment indicator based on the 
currently available data regarding 
individuals’ treatment preferences; and 
3) determine the predictive accuracy 
of the preliminary population-based 
treatment indicator.
How Accurate Are Surrogates?
The best way to assess how accurately 
surrogates predict patients’ treatment 
preferences would be to determine 
how closely surrogates’ treatment 
decisions match patients’ preferences 
at the time patients are incapacitated. 
Because there is no way to determine 
what medical treatments patients want 
at the time they are incapacitated, most 
empirical studies assess how accurately 
surrogates predict patients’ treatment 
choices in hypothetical scenarios. 
A recent article systematically 
analyzed the 16 empirical studies 
published in English that used this 
methodology [18]. Each study posed 
hypothetical scenarios in which the 
patient would be unable to make 
medical decisions. Patients were asked 
whether, in these scenarios, they 
would want to receive various medical 
interventions, such as ventilation and 
cardiopulmonary resuscitation (CPR). 
Each surrogate was then independently 
asked to predict what choices 
the patient made in the included 
scenarios. The 16 analyzed studies 
presented a total of 151 hypothetical 
scenarios to 2,595 surrogate–patient 
pairs, collectively analyzing 19,526 
paired patient–surrogate responses. 
More than 90% of the 151 scenarios 
involved an intervention necessary 
to save or sustain the patient’s life. 
For example, one study posed the 
following scenario [19]:
You recently suffered a major stroke 
leaving you in a coma and unable to 
breathe without a machine. After a few 
months, the doctor determines that it 
is unlikely that you will come out of the 
coma. If your doctor had asked whether 
to try to revive you if your heart 
stopped beating in this situation, what 
would you have told the doctor to do?
Analysis of the 16 studies reveals that 
surrogates accurately predict patients’ 
treatment preferences approximately 
68% of the time. 
The empirical data also suggest that 
the two most frequently endorsed 
methods for improving surrogates’ 
predictive accuracy—reliance on 
surrogates designated by the patient 
rather than the default next of kin, 
and explicit discussion of patients’ 
treatment preferences—are ineffective. 
In the studies conducted, surrogates 
designated by the patient were no more 
accurate than surrogates appointed 
according to the relevant state’s “next-
of-kin” relationship hierarchy. Similarly, 
explicit discussion of patients’ treatment 
preferences did not increase surrogates’ 
ability to predict patients’ treatment 
choices. Finally, several studies ﬁ  nd 
that physicians are even less accurate 
than surrogates at predicting patients’ 
treatment preferences [20–22].
Developing a Population-Based 
Treatment Indicator
To identify data for a preliminary 
population-based treatment indicator, 
we searched the existing published 
literature for empirical data on 
individuals’ medical treatment 
preferences. This search identiﬁ  ed a 
few relevant studies. Polling results 
suggest patients’ preferences for 
receiving a given intervention are 
correlated with their predicted post-
intervention health state [23,24]. 
When it is predicted that the patient 
will return to an acceptable health 
state, the majority of patients want to 
receive most interventions. When it 
is predicted that the patient will end 
up in an unacceptable health state, 
the majority of patients decline most 
interventions. 
These ﬁ  ndings raised the question of 
which health states individuals regard 
as acceptable, and which they regard as 
unacceptable. Further research found 
that most Americans consider being 
permanently in a coma or otherwise 
permanently unable to reason, 
remember, or communicate as no 
better than, or even worse than death 
[8,25,26], and would not want life-
saving interventions in these situations 
[27–29]. For example, one national 
survey reported that 75% of 1,311 
adults would not want to be kept alive 
if they were in a coma with no chance 
of recovery [27]. Data also suggest 
that many Americans want life-saving 
interventions when there is at least a 
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1% chance that the treatment will lead 
to what they consider an acceptable 
health state [30]. 
Putting these ﬁ  ndings together, we 
deﬁ  ned a preliminary population-based 
treatment indicator which predicts 
that a given patient will want life-saving 
treatment when there is at least a 1% 
chance, following the intervention, 
that the patient will reach a health 
state which includes the ability to 
reason, remember, and communicate. 
Conversely, the preliminary population-
based treatment indicator predicts 
that patients will not want life-saving 
treatments when there is greater than 
a 99% chance that, following the 
treatment, they will be left permanently 
unable to reason, remember, or 
communicate.
The data we identiﬁ  ed concern 
the treatment preferences of US 
citizens in general, and do not provide 
information on the characteristics 
of individuals who have different 
treatment preferences. For example, 
the data show that most Americans 
would not want life-saving treatment 
if they would be left unable to reason, 
remember, or communicate. Based 
on this ﬁ  nding, our preliminary 
population-based treatment indicator 
predicts that a given patient would 
not want life-saving treatment if they 
were in a coma. While this prediction 
matches the preferences of the majority 
of Americans, it fails to identify 
Americans who would want life-saving 
treatment even in the presence of a 
coma. Collection of additional data 
to identify the characteristics of these 
individuals would yield a more accurate 
treatment indicator.
Comparing Surrogates to a 
Population-Based Treatment 
Indicator
To determine the predictive accuracy 
of our preliminary population-based 
treatment indicator, we evaluated its 
accuracy in the scenarios used by the 
extant empirical studies to evaluate 
surrogate accuracy. We ﬁ  rst selected 
all the scenarios that provided both 
surrogates’ percentage predictive 
accuracy and the percentage of patients 
who wanted the offered intervention. 
The accuracy of the treatment 
indicator was calculated by determining 
the percentage of cases in which the 
prediction of the population-based 
treatment indicator would match 
the patient’s treatment preference. 
This accuracy was then compared 
to the percentage of surrogates who 
accurately predicted the patient’s 
treatment preferences.
Scenarios were excluded from this 
comparison if they 1) did not involve 
a life-saving intervention; 2) did not 
describe the proposed intervention 
or the patient’s predicted post-
intervention health state; 3) included 
a post-intervention health state 
that is not addressed by the current 
data on which health states the US 
general public ﬁ  nds acceptable; or 
4) did not provide data on patients’ 
preferences for receiving the proposed 
intervention. For a complete list of 
scenarios included in the comparison, 
see Table 1.
Many of the scenarios used in the 
empirical studies do not provide 
Table 1. Scenarios Included in the Surrogate/Treatment Indicator Comparison
Scenario ID Number of Studies Which 
Include Scenario
% Patients 
Refusing 
Intervention
% Agreement Health State Intervention Outcomes 
Categorized as 
Acceptable
1 4 75 74 Coma ANH
2 1 86 75 Coma Antibiotics
3 6 75 75 Coma CPR
4 1 68 72 Coma Dialysis
5 1 74 73 Coma GBS
6 1 58 70 Coma ICU
7 5 81 78 Coma Intubation
8 1 48 50 Coma Surgery
9 1 17 77 Current Health ANH X
10 2 0 98 Current Health Antibiotics X
11 4 14 87 Current Health CPR X
12 1 2 96 Current Health GBS X
13 1 2 88 Current Health Hospitalization X
14 1 10 90 Current Health ICU X
15 1 10 87 Current Health IV ﬂ  uids X
16 1 23 64 Current Health Intubation X
17 1 66 70 Dementia ANH
18 2 48 66 Dementia CPR
19 1 61 67 Dementia Dialysis
20 1 51 65 Dementia ICU
21 1 65 65 Dementia Intubation
22 2 74 77 PVS ANH
23 1 62 67 PVS Antibiotics
24 1 71 76 PVS CPR
25 1 71 65 PVS Dialysis
26 1 62 67 PVS Hospitalization
27 1 62 66 PVS ICU
28 1 67 73 PVS IV ﬂ  uids
29 1 84 81 PVS Intubation
ANH, artiﬁ  cial nutrition and hydration; GBS, gall bladder surgery; ICU, admission to the intensive care unit; IV, intravenous; PVS, persistent vegetative state
doi:10.1371/journal.pmed.0040035.t001
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quantitative estimates of patients’ 
prognoses. One scenario asks patients 
whether they would want various life-
saving interventions if it was “unlikely” 
they would come out of a coma or 
if “no one can be certain what [the 
patient’s] level of functioning would 
be if she ever did come out of the 
coma [31].” To provide the most 
complete test possible, we deﬁ  ned 
the preliminary population-based 
treatment indicator to predict that 
patients do not want life-saving 
interventions when the likelihood 
of recovery or the predicted health 
outcome are described in negative 
terms. Conversely, we deﬁ  ned it to 
predict that patients want life-saving 
interventions when the likelihood of 
recovery and the predicted health 
outcome are described in positive 
terms.
Analysis reveals that this very 
preliminary population-based 
treatment indicator predicts patients’ 
treatment preferences with essentially 
the same accuracy as surrogates (Table 
2). Overall, the treatment indicator 
correctly predicted the patient’s 
treatment preferences in 78.5% of 
cases, while, in these same scenarios, 
surrogates correctly predicted the 
patient’s treatment preferences in 
78.4% of cases. We hypothesize that 
the accuracy of surrogates in these 
scenarios is inﬂ  ated relative to the 
review’s overall ﬁ  ndings (i.e., 78% 
versus 68%) because many of the 
scenarios selected for comparison were 
“easier” than the excluded scenarios, 
involving the patient’s current health 
and hypothetical health states and 
interventions with which the general 
public is familiar, such as coma and 
CPR. 
Reﬁ  ning the Population-Based 
Treatment Indicator
Our preliminary population-based 
treatment indicator is limited, in 
several ways, by the existing data. First, 
our preliminary version is based on the 
preferences of the US general public. 
The present data did not allow us to 
deﬁ  ne a preliminary indicator that 
takes into account the fact that certain 
groups, especially cultural and religious 
groups, systematically have different 
preferences for medical treatment at 
the end of life compared to the general 
population [32]. Second, the present 
data did not allow us to incorporate 
the fact that the characteristics of 
individual patients, including age 
and gender [33], and aspects of the 
patient’s post-intervention health 
state, beyond the ability to reason, 
remember, and communicate, often 
inﬂ  uence whether they want to receive 
medical treatments. Patients may want 
to be treated when there is essentially 
any chance of returning to complete 
health, but insist on a higher chance 
of success when the predicted health 
outcome includes a serious disability, 
such as complete paralysis of the lower 
limbs. 
Third, data indicate that individuals’ 
preferences for receiving medical 
interventions are inﬂ  uenced by the 
characteristics of the interventions 
themselves [34]. Patients are more 
likely to decline invasive procedures 
(e.g., intubation) compared to 
less invasive procedures (e.g., oral 
medications). Given the current paucity 
of systematic data, we were unable to 
incorporate these considerations in our 
preliminary treatment indicator. 
While the preliminary treatment 
indicator likely could be made more 
accurate by incorporating data on these 
factors, the two most widely endorsed 
methods for improving surrogate 
accuracy—values discussions and 
patient-designation of surrogates—
appear ineffective [18]. Moreover, 
current estimates, which are based on 
hypothetical scenarios, may represent 
an overestimate of surrogates’ true 
predictive accuracy. Surrogates may 
be comparatively less able to process 
the medical facts relevant to making 
treatment decisions for incapacitated 
patients in actual cases. And surrogates 
may be less able to reason clearly 
when faced with the stress, sorrow, and 
uncertainty that accompany caring for 
loved ones at the end of life.
Using the Population-Based 
Treatment Indicator
When the treatment preferences of an 
incapacitated patient are unknown, 
the clinician would enter the patient’s 
characteristics and circumstances into 
the database of the population-based 
treatment indicator. The indicator 
provides a statistical prediction of 
which treatment option the patient 
would want based on the treatment 
preferences of similar patients in 
similar situations. In practice, this 
prediction could be used in at least 
three ways.
First, the treatment prediction 
might supplement the surrogate 
decision-making process. In this 
approach, treatment decisions for 
incapacitated patients would still be 
made in consultation with the patient’s 
surrogate. The population-based 
treatment indicator would be used to 
help diminish uncertainty surrounding 
the patient’s wishes by identifying the 
treatment preferred by similar patients. 
For example, when the patient’s 
preferences are unknown, it likely would 
be useful for physicians and surrogates 
to know that 90% of individuals like 
the patient want to be intubated in the 
patient’s situation. This approach might 
help to relieve some of the burdens 
associated with making decisions for 
incapacitated patients, while allowing 
family and loved ones to retain ﬁ  nal 
decision-making authority.
More radically, the population-
based treatment indicator could be 
used in place of surrogate decision 
Table 2. Predictive Accuracy of Surrogates Versus a Preliminary Population-Based 
Treatment Indicator
Accuracy (95% CI)
Overalla
Surrogates 78.4% (73, 84)
Treatment indicator 78.5% (72, 85)
Unacceptable outcomesb
Surrogates 73.0% (69, 76)
Treatment indicator 72.7% (67, 78)
Acceptable outcomesc
Surrogates 90.3% (82, 99)
Treatment indicator 91.0% (86, 96)
a29 different scenarios; 47 scenarios total. 
b21 different scenarios; 35 scenarios total.
c8 different scenarios; 12 scenarios total.
CI, credible interval
doi:10.1371/journal.pmed.0040035.t002
March 2007  |  Volume 4  |  Issue 3  |  e35PLoS Medicine  |  www.plosmedicine.org 0427
makers. When the patient’s treatment 
preferences are unknown, treatment 
decisions would be based on the 
prediction of the population-based 
treatment indicator. Finally, competent 
individuals could be asked to indicate 
on their advance directives whether, 
in the event of incapacity, they prefer 
to have treatment decisions made by a 
designated surrogate, or based on the 
population-based treatment indicator. 
Since not all individuals complete 
advance directives this method would 
have to be supplemented with a default 
approach.
Who Should Make Treatment 
Decisions for Incapacitated 
Patients?
The fact that a preliminary treatment 
indicator is as accurate as surrogates, 
and the accuracy of the treatment 
indicator could be increased with the 
collection of more systematic data, 
suggests that a reﬁ  ned population-
based treatment indicator likely would 
predict patients’ treatment preferences 
more accurately than surrogates. 
This conclusion reveals that the most 
important considerations do not all 
point to the family and loved ones as 
the appropriate decision makers for 
incapacitated patients. While allowing 
intimate others to have a say in the 
care of incapacitated patients supports 
current reliance on surrogates, 
accuracy in matching treatment 
decisions to patients’ preferences 
supports the use of a population-based 
treatment indicator. 
To determine which approach 
clinicians should adopt, it will be 
necessary to conduct additional 
research. Normative analysis will be 
needed to prioritize the relevant 
considerations: what is more important, 
which treatment decisions get made, or 
who makes them? Ideally, this analysis 
should be informed by empirical data 
on the preferences of individuals and 
family members, as well as data on 
the impact that making end-of-life 
treatment decisions has on family 
and loved ones. To what extent does 
making decisions for incapacitated 
patients allow families and loved ones 
to process a tragic event, and to what 
extent does it represent an unwelcome 
burden at a time of extraordinary 
stress? The few studies to directly 
assess the impact of decision making 
on surrogates do not indicate whether 
making treatment decisions is, overall, 
beneﬁ  cial or burdensome [35–37]. 
Future studies might compare 
the beneﬁ  ts and burdens surrogates 
experience when they make treatment 
decisions versus the impact of using a 
population-based treatment indicator. 
A ﬁ  nding that family members 
experience important beneﬁ  ts 
would provide an important reason 
to continue to rely on surrogates. A 
ﬁ  nding that family members do much 
better if clinicians rely on population-
based treatment aids would provide an 
important reason to consider pursuing 
this approach. 
We do not know why surrogates are 
frequently inaccurate when predicting 
their charges’ treatment preferences. 
More research should consider this 
issue and whether it might be possible 
to identify other ways to improve 
surrogate accuracy. Finally, US states 
have their own laws regarding how 
treatment decisions should be made for 
incapacitated patients. Changes in the 
method of making treatment decisions 
for incapacitated patients may require 
changes to these laws.
Conclusion
Current reliance on surrogates gains 
support from the fact that the four 
most important considerations—
respect for family and loved ones, 
impact on family and loved ones, 
respect for patients’ treatment 
preferences, and respect for patients’ 
preferences regarding who makes 
treatment decisions for them—all 
seem to point to the patient’s family 
and loved ones as the appropriate 
decision makers for incapacitated 
patients. However, systematic analysis 
suggests that a preliminary population-
based treatment indicator, one based 
on currently available data, predicts 
patients’ preferences as accurately as 
surrogates, and implies that a reﬁ  ned 
treatment indicator which took into 
account additional data on individuals’ 
treatment preferences likely would 
predict incapacitated patients’ 
preferences more accurately than 
surrogates.
This conclusion reveals that 
identiﬁ  cation of a best practice 
requires prioritization of the relevant 
considerations regarding who 
should make treatment decisions for 
incapacitated patients. Normative 
analysis on this question should be 
informed by empirical data. Do patients 
care more about who makes decisions 
for them, or what decisions are made? 
Does making end-of-life treatment 
decisions beneﬁ  t or burden families 
and loved ones overall?  
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